Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC)

31 August 2023 – The safety committee of the European Medicines Agency recommends new measures to avoid exposure of children to topiramate-containing medicines in the womb, because the medicine may increase the risk of neurodevelopmental problems after exposure during pregnancy. Topiramate is already known to cause serious birth defects when used during pregnancy.

For more information, see here.